These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27113955)

  • 1. Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Kunwar S; Devkota AR; Ghimire DK
    Rheumatol Int; 2016 Aug; 36(8):1077-87. PubMed ID: 27113955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
    Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
    Scott DL
    Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
    Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
    Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study.
    Tanaka Y; Millson D; Iwata S; Nakayamada S
    Rheumatology (Oxford); 2021 Jun; 60(6):2884-2895. PubMed ID: 33254235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
    Weinblatt ME; Kavanaugh A; Genovese MC; Jones DA; Musser TK; Grossbard EB; Magilavy DB
    J Rheumatol; 2013 Apr; 40(4):369-78. PubMed ID: 23378467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
    Maringwa J; Kågedal M; Hamrén UW; Martin P; Cox E; Hamrén B
    J Clin Pharmacol; 2015 Mar; 55(3):328-35. PubMed ID: 25280085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.
    Genovese MC; van der Heijde DM; Keystone EC; Spindler AJ; Benhamou C; Kavanaugh A; Fudman E; Lampl K; O'Brien C; Duffield EL; Poiley J; Weinblatt ME
    J Rheumatol; 2014 Nov; 41(11):2120-8. PubMed ID: 25225285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
    Kunwar S; Dahal K; Sharma S
    Rheumatol Int; 2016 Aug; 36(8):1065-75. PubMed ID: 27105880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The status of fostamatinib in the treatment of rheumatoid arthritis.
    Morales-Torres J
    Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
    Scott IC; Scott DL
    Drugs; 2014 Mar; 74(4):415-22. PubMed ID: 24610702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.
    Kitas GD; Abreu G; Jedrychowicz-Rosiak K; Miller JL; Nakov R; Panfilov S; Vencovsky J; Wang M; Weinblatt ME; White WB
    J Am Soc Hypertens; 2014 Nov; 8(11):780-90. PubMed ID: 25455003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Weinblatt ME; Kavanaugh A; Genovese MC; Musser TK; Grossbard EB; Magilavy DB
    N Engl J Med; 2010 Sep; 363(14):1303-12. PubMed ID: 20879879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis.
    Nijjar JS; Tindell A; McInnes IB; Siebert S
    Rheumatology (Oxford); 2013 Sep; 52(9):1556-62. PubMed ID: 23861534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
    Kunwar S; Collins CE; Constantinescu F
    Clin Rheumatol; 2018 Oct; 37(10):2611-2620. PubMed ID: 30006916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials.
    Tungjitviboonkun S; Bumrungratanayos N; Jitwimungsanon J; Kheamakulvanich T; Siramongkholkarn S
    Ann Hematol; 2024 Sep; 103(9):3357-3368. PubMed ID: 38856778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.
    Boström E; Öhrn F; Hanze E; Sandström M; Martin P; Wählby-Hamrén U
    J Clin Pharmacol; 2014 Dec; 54(12):1337-46. PubMed ID: 24895144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
    Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
    Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
    Bajpai M
    IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Kang Y; Jiang X; Qin D; Wang L; Yang J; Wu A; Huang F; Ye Y; Wu J
    Front Pharmacol; 2019; 10():897. PubMed ID: 31474860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.